Skip to main content
TipRanks
Go Ultimate75% OFF

Anavex Life Sciences (12X1) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Anavex Life Sciences has a market cap or net worth of CHF 72.61M. The enterprise value is CHF 122.28M.

Market Cap
CHF 72.61M
Enterprise Value
CHF 122.28M

Share Statistics

Anavex Life Sciences has 92,696,840 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
92,696,840
Owned by Insiders
1.66%
Owned by Institutions
32.65%

Financial Efficiency

Anavex Life Sciences’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -54.19%.

Return on Equity (ROE)
-0.49
Return on Assets (ROA)
-0.45
Return on Invested Capital (ROIC)
-54.19%
Return on Capital Employed (ROCE)
-0.54
Revenue Per Employee
0
Profits Per Employee
-1.36M
Employee Count
34
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Anavex Life Sciences is -6.35. Anavex Life Sciences’s PEG ratio is -0.05.

PE Ratio
-6.35
PS Ratio
0.00
PB Ratio
0.77
Price to FCF
-2.57
Price to Operating Cash Flow
-2.57
PEG Ratio
-0.05

Income Statement

In the last 12 months, Anavex Life Sciences had revenue of 0 and earned -46.38M in profits. Earnings per share was -0.54.

Revenue
0
Gross Profit
0
Operating Income
-51.41M
Pretax Income
-46.38M
Net Income
-46.38M
EBITDA
-46.38M
Earnings Per Share (EPS)
-0.54

Cash Flow

In the last 12 months, operating cash flow was -33.73M and capital expenditures 0, giving a free cash flow of -33.73M billion.

Operating Cash Flow
-33.73M
Free Cash Flow
-33.73M
Free Cash Flow per Share
-0.36

Dividends & Yields

Anavex Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-38.98%
Earnings Yield
-15.05%

Stock Price Statistics

Beta
2.00
52-Week Price Change
―
50-Day Moving Average
―
200-Day Moving Average
―
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Anavex Life Sciences upcoming earnings date is Nov 30, 2026, TBA (Not Confirmed).

Last Earnings Date
Jul 30, 2026
Next Earnings Date
Nov 30, 2026
Ex-Dividend Date
―

Financial Position

Anavex Life Sciences as a current ratio of 11.60, with Debt / Equity ratio of 0.00%

Current Ratio
11.60
Quick Ratio
11.60
Debt to Market Cap
0.00
Net Debt to EBITDA
2.21
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Anavex Life Sciences has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Anavex Life Sciences EV to EBITDA ratio is 2.94, with an EV/FCF ratio of 0.94.

EV to Sales
0.00
EV to EBITDA
2.94
EV to Free Cash Flow
0.94
EV to Operating Cash Flow
0.94

Balance Sheet

Anavex Life Sciences has CHF 118.33M in cash and marketable securities with CHF 0.00 in debt, giving a net cash position of CHF 118.33M billion.

Cash & Marketable Securities
CHF 118.33M
Total Debt
CHF 0.00
Net Cash
CHF 118.33M
Net Cash Per Share
CHF 1.28
Tangible Book Value Per Share
CHF 1.21

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Anavex Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
73.28%

Scores

Smart Score
1
AI Score
―